Combining Toripalimab with Cryoablation for Advanced Lung Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of toripalimab, a PD-1 inhibitor, in combination with cryoablation for patients with driver-negative advanced non-small cell lung cancer (NSCLC) who experience oligoprogression after first-line therapy. The study aims to determine if this combination can enhance immune response and improve disease control in patients with limited metastatic lesions. Participants will undergo treatment and be monitored for outcomes related to tumor response and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntary participation and written informed consent;
* histologically or cytologically confirmed advanced metastatic (stage IV) non-small cell lung cancer;
* Patients with negative driver genes who develop oligoprogression after receiving standard first-line therapy. The oligoprogression is defined as: 1-5 metastatic lesions, and no more than 3 organs;
* Age 18-75 years old; ECOG PS: 0-1; The expected survival is more than 3 months;
* At least one measurable lesion;
* Patients were willing to provide adequate blood and tissue samples；
* Patients had adequate hematologic, renal, and liver function;
* International normalised ratio (INR) ≤1.5 and partial thromboplastin time (PTT or aPTT) ≤1.5 x ULN within 7 days prior to study treatment;
* The woman patients of childbearing age who must agree to take contraceptive methods during the research;
* The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.

Exclusion Criteria:

* cytologically or histologically confirmed combination with small cell lung cancer component or sarcomatoid element;
* Previously received targeted therapy for advanced NSCLC (including osimertinib, erlotinib, crizotinib, etc);
* Had undergone major surgical operations or had not fully recovered from previous operations within 3 weeks before enrollment;
* Known active nervous system (CNS) metastases and/or carcinomatous meningitis;
* Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression;
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; patients with stable symptoms after drainage can be enrolled;
* History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening;
* Clinically uncontrolled active infection, including but not limited to acute pneumonia;
* Uncontrollable major epileptic seizure or superior vena cava syndrome;
* Previous or current co-occurrence of other malignancies (excluding controllable non-melanoma basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the breast or cervix, superficial bladder cancer, or other carcinoma in situ);
* Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease;
* Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening;
* Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle;
* Vaccination of live-virus vaccine within 30 days after the start of planned treatment; Inactivated seasonal influenza vaccine was permitted;
* Patients has HIV-positive;
* Patients judged by the investigator to be inappropriate as a subject of this study.
* History of severe allergic, quasi-allergic, or other hypersensitive reactions to chimeric or humanized antibodies or fusion proteins;
* Known allergy to biological drugs produced from Chinese hamster ovary cells, or to citrate monohydrate, sodium citrate dihydrate, mannitol, polysorbate (components of the study drug);
* Patients who have previously received allogeneic stem cells or parenchymal organ transplants.

Where it's running

• Shanghai Chest Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Not yet recruiting
• Zhongshan Hospital, Fudan University
  Shanghai, China Not yet recruiting

Study contacts

• Study coordinator: Ziming Li, Doctor
• Email: liziming1980@163.com
• Phone: 0086-13764590226

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations

  This study is testing if a combination of a new immunotherapy drug and chemotherapy can help people with localized lung cancer that has rare mutations by seeing if it can completely eliminate the tumor.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guanzhou, Guangdong · NCT05800340

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.